Moors & Cabot Inc. boosted its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 1.8% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 14,709 shares of the company’s stock after buying an additional 254 shares during the quarter. Moors & Cabot Inc.’s holdings in Zoetis were worth $2,550,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of ZTS. Montag & Caldwell LLC increased its holdings in Zoetis by 4.1% during the second quarter. Montag & Caldwell LLC now owns 123,832 shares of the company’s stock worth $21,468,000 after buying an additional 4,934 shares during the last quarter. Mesirow Financial Investment Management Inc. increased its stake in shares of Zoetis by 1.5% during the 2nd quarter. Mesirow Financial Investment Management Inc. now owns 40,040 shares of the company’s stock worth $6,949,000 after purchasing an additional 579 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Zoetis by 15.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,165,958 shares of the company’s stock valued at $375,548,000 after purchasing an additional 294,326 shares during the period. Fairfield Financial Advisors LTD acquired a new stake in Zoetis in the 2nd quarter valued at about $262,000. Finally, Quilter Plc grew its holdings in Zoetis by 12.6% during the second quarter. Quilter Plc now owns 280,032 shares of the company’s stock worth $48,546,000 after purchasing an additional 31,299 shares during the period. 92.80% of the stock is currently owned by institutional investors.
Zoetis Stock Performance
NYSE ZTS opened at $195.74 on Wednesday. The firm has a 50-day moving average price of $183.65 and a two-hundred day moving average price of $174.15. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company has a market capitalization of $88.68 billion, a P/E ratio of 37.71, a P/E/G ratio of 2.98 and a beta of 0.88. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on the company. Piper Sandler raised their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research raised their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, Stifel Nicolaus restated a “buy” rating and set a $200.00 target price on shares of Zoetis in a research note on Tuesday, August 27th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average price target of $217.11.
Read Our Latest Stock Report on Zoetis
Zoetis Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Articles
- Five stocks we like better than Zoetis
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- How to Find Undervalued Stocks
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Earnings Per Share Calculator: How to Calculate EPS
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.